Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new era for Parkinson's treatment: The FDA approved tavapadon (Juvmo; AbbVie) in September 2026 — the first dopamine agonist to selectively target D1/D5 receptors rather than the D2/D3 receptors of existing drugs. Backed by the phase 3 TEMPO trial program, it showed meaningful motor improvements in early PD and increased ON time in patients on levodopa, with a tolerability profile that notably avoids the sleep attacks and somnolence common with older agonists.
A new era for Parkinson's treatment
The FDA approved tavapadon (Juvmo; AbbVie) in September 2026 — the first dopamine agonist to selectively target D1/D5 receptors rather than the D2/D3 receptors of all existing agonists. The once-daily oral therapy can be used as monotherapy in early Parkinson's disease (PD) or as an add-on to levodopa in patients experiencing motor fluctuations, giving clinicians flexibility across the treatment journey.
The approval was supported by the phase 3 TEMPO program across three pivotal trials. In early PD, tavapadon significantly improved motor function and daily living scores versus placebo. In patients already on levodopa, it added meaningful ON time without worsening troublesome dyskinesia. The drug's D1/D5 selectivity appears to sidestep some of the most burdensome side effects of older agonists — particularly somnolence and sleep attacks — though titration-phase side effects like nausea and dizziness remain, and prescribing information carries warnings for hallucinations, orthostatic hypotension, and impulse control behaviors.
By the Numbers:
Why it matters: Tavapadon is the first novel mechanism approved for PD in years, offering a new option that may help delay levodopa escalation and reduce nonmotor side effects — a meaningful step forward for patients and clinicians navigating a complex, progressive disease.
